2-bromo-5-(1-pyrrolidinylmethyl)pyridine | 742085-62-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-bromo-5-(1-pyrrolidinylmethyl)pyridine
• 英文别名: 2-bromo-5-(pyrrolidin-1-ylmethyl)pyridine
• CAS: 742085-62-7
• 化学式: C₁₀H₁₃BrN₂
• 分子量: 241.131
• InChiKey: CQLIMWGELSTYMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(4-甲氧基苯基)噁唑 、 2-bromo-5-(1-pyrrolidinylmethyl)pyridine 在 copper(l) iodide 、 sodium carbonate 、 三苯基膦 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Structure–Activity Relationships of New Natural Product-Based Diaryloxazoles with Selective Activity against Androgen Receptor-Positive Breast Cancer Cells

  摘要：

  Targeted therapies for ER+/PR+ and HER2-amplified breast cancers have improved patient survival, but there are no therapies for triple negative breast cancers (TNBC) that lack expression of estrogen and progesterone receptors (ER/PR), or amplification or overexpression of HER2. Gene expression profiling of TNBC has identified molecular subtypes and representative cell lines. An extract of the Texas native plant Amyris texana was found to have selective activity against MDA-MB-453 cells, a model of the luminal androgen receptor (LAR) subtype of TNBC. Bioassay-guided fractionation identified two oxazole natural products with selective activity against this cell line. Conducted analog synthesis and structure activity relationship studies provided analogs with more potent and selective activity against two LAR. subtype cell line models, culminating in the discovery of compound 30 (CIDD-0067106). Lead compounds discovered have potent and selective antiproliferative activities, and mechanisms of action studies show they inhibit the activity of the mTORC1 pathway.

  DOI：

  10.1021/acs.jmedchem.7b01228
• 作为产物：
  描述：

  四氢吡咯 、 2-溴-5-(溴甲基)吡啶 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 6.0h， 生成 2-bromo-5-(1-pyrrolidinylmethyl)pyridine
  参考文献：
  名称：

  EP1593667

  摘要：

  公开号：

文献信息

• [EN] TAM KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES TAM
  申请人：SYROS PHARMACEUTICALS INC

  公开号：WO2018191587A1

  公开（公告）日：2018-10-18

  Described herein are compounds, methods of making such compounds, compositions (e.g., pharmaceutical compositions/medicaments) that include such compounds, and methods of using such compounds to treat diseases, such as cancer.

  本文描述了化合物，制备这种化合物的方法，包括这种化合物的组合物（例如，包含这种化合物的药物组合物/药物），以及使用这种化合物治疗疾病（如癌症）的方法。
• MODULATORS OF TOLL-LIKE RECEPTORS
  申请人：Halcomb Randall L.

  公开号：US20110098248A1

  公开（公告）日：2011-04-28

  The present application includes novel modulators of TLRs, compositions containing such compounds, therapeutic methods that include the administration of such compounds.

  本申请涵盖了TLR的新型调节剂，包含这类化合物的组合物，以及包括这类化合物的给药的治疗方法。
• Amine derivative
  申请人：Ishihara Yuji

  公开号：US20060128690A1

  公开（公告）日：2006-06-15

  The present invention provides a compound represented by the formula wherein Ar 1 is a cyclic group optionally having substituent(s); R is a hydrogen atom, an optionally halogenated C 1-6 alkyl, a phenyl optionally having substituent(s) or a pyridyl optionally having substituent(s); Ra 1 , Ra 2 , Ra 3 and Ra 4 are the same or different and each is a hydrogen atom, an optionally halogenated C 1-6 alkyl or the like; Ar is a monocyclic aromatic ring optionally having substituent(s); Y is an optionally halogenated alkylene group; and R 1 and R 2 are (1) the same or different and each is a hydrogen atom or a C 1-6 alkyl, (2) R 1 and R 2 form a nitrogen-containing heterocycle optionally having substituent(s) together with the adjacent nitrogen atom, or (3) R 1 and Y form a nitrogen-containing heterocycle optionally having substituent(s) together with the adjacent nitrogen atom, and R 2 is a hydrogen atom or a C 1-6 alkyl; provided that when the nitrogen-containing heterocycle formed by R 1 and R 2 together with the adjacent nitrogen atom is a piperazine, or when R is a C 1-4 alkyl, Ar 1 is a cyclic group having substituent(s), or a salt thereof, having a melanin-concentrating hormone antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like.

  本发明提供了一种化合物，其表示为式子： 其中，Ar1是一个环状基团，可以具有取代基；R是氢原子，可选卤代的C1-6烷基，苯环，可以具有取代基，或者吡啶环，可以具有取代基；Ra1，Ra2，Ra3和Ra4相同或不同，每个都是氢原子，可选卤代的C1-6烷基或类似物；Ar是一个单环芳香环，可以具有取代基；Y是可选卤代的脂肪族烷基；R1和R2是（1）相同或不同，每个都是氢原子或C1-6烷基，（2）R1和R2与相邻的氮原子一起形成含氮杂环，可以具有取代基，或（3）R1和Y与相邻的氮原子一起形成含氮杂环，可以具有取代基，并且R2是氢原子或C1-6烷基；但是当R1和R2与相邻的氮原子一起形成哌嗪环，或当R是C1-4烷基，Ar1是具有取代基的环状基团或其盐时，该化合物具有黑色素浓集激素拮抗作用，可用作预防或治疗肥胖症等药物。
• AMINE DERIVATIVE
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1593667A1

  公开（公告）日：2005-11-09

  The present invention provides a compound represented by the formula wherein Ar1 is a cyclic group optionally having substituent(s); R is a hydrogen atom, an optionally halogenated C1-6 alkyl, a phenyl optionally having substituent(s) or a pyridyl optionally having substituent(s); Ra1, Ra2, Ra3 and Ra4 are the same or different and each is a hydrogen atom, an optionally halogenated C1-6 alkyl or the like; Ar is a monocyclic aromatic ring optionally having substituent(s); Y is an optionally halogenated alkylene group; and R1 and R2 are (1) the same or different and each is a hydrogen atom or a C1-6 alkyl, (2) R1 and R2 form a nitrogen-containing heterocycle optionally having substituent(s) together with the adjacent nitrogen atom, or (3) R1 and Y form a nitrogen-containing heterocycle optionally having substituent(s) together with the adjacent nitrogen atom, and R2 is a hydrogen atom or a C1-6 alkyl; provided that when the nitrogen-containing heterocycle formed by R1 and R2 together with the adjacent nitrogen atom is a piperazine, or when R is a C1-4 alkyl, Ar1 is a cyclic group having substituent(s), or a salt thereof, having a melanin-concentrating hormone antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like.

  本发明提供了一种由式表示的化合物 其中 Ar1 是任选具有取代基的环状基团； R 是氢原子、任选卤化的 C1-6 烷基、任选具有取代基的苯基或任选具有取代基的吡啶基； Ra1、Ra2、Ra3 和 Ra4 相同或不同，各自为氢原子、任选卤代的 C1-6 烷基或类似物； Ar 是单环芳香环，可选择具有取代基； Y 是任选卤代亚烷基；以及 R1 和 R2 (1) 相同或不同，且各自为氢原子或 C1-6 烷基；(2) R1 和 R2 组成含氮杂环，可选择与相邻氮原子一起具有取代基；或 (3) R1 和 Y 组成含氮杂环，可选择与相邻氮原子一起具有取代基，且 R2 为氢原子或 C1-6 烷基； 条件是当 R1 和 R2 与相邻氮原子一起形成的含氮杂环是哌嗪时，或当 R 是 C1-4 烷基时，Ar1 是具有取代基的环状基团或其盐，具有黑色素浓缩激素拮抗作用，可用作预防或治疗肥胖症等的药物。
• Triazolopyrimidine compounds and their use in treating cancer
  申请人：Dizal (Jiangsu) Pharmaceutical Co., Ltd.

  公开号：US11084827B2

  公开（公告）日：2021-08-10

  The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Ring A, Ring B and Ring C have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating MCT4 mediated diseases.

  本发明涉及式（I）化合物： 或其药学上可接受的盐，其中 R1、R2、X、环 A、环 B 和环 C 具有本文在描述中定义的任何含义；它们的制备工艺；含有它们的药物组合物以及它们在治疗 MCT4 介导的疾病中的用途。